BridgeBio Highlights Acoramidis Efficacy with Real-World Data at HFSA 2026
Event summary
- BridgeBio will present 10 new data sets on acoramidis at the HFSA Annual Scientific Meeting 2026, including real-world EHR data.
- Acoramidis is positioned as the first-line treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).
- The drug is approved under multiple brands (Attruby® in the U.S., BEYONTTRA® in Europe and other regions).
- Presentations include comparative effectiveness studies against rival tafamidis.
- Key focus areas: mortality risk reduction, cardiovascular hospitalization impacts, and long-term cardiac function effects.
The big picture
BridgeBio is reinforcing acoramidis' clinical profile through real-world evidence, a critical strategy in the competitive ATTR-CM space. The focus on comparative effectiveness against tafamidis positions BridgeBio to potentially capture market share in this niche but growing genetic cardiovascular disease segment. The decentralized model allows rapid deployment of these findings across multiple regulatory jurisdictions.
What we're watching
- Competitive Positioning
- How BridgeBio's real-world data will affect acoramidis' market share against established tafamidis.
- Regulatory Expansion
- Whether the positive data will accelerate approvals in additional markets.
- Clinical Adoption
- The pace at which physicians adopt acoramidis as first-line treatment based on these findings.